Secorapamycin A
CAS: 147438-27-5
Ref. 3D-XFA43827
1mg | A consultar | ||
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar | ||
50mg | A consultar |
Informação sobre produto
- 2-Piperidinecarboxylicacid, 1-[oxo[(2R,3R,6S)-tetrahydro-2-hydroxy-6-[(2S,3E,5E,7E,9S,11R,13R,14R,15E,17R,19E,21R)-14-hydroxy-22-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-2,13-dimethoxy-3,9,11,15,17,21-hexamethyl-12,18-dioxo-3,5,7,15,19-docosapentaenyl]-3-methyl-2H-pyran-2-yl]acetyl]-(9CI)
- 2-Piperidinecarboxylic acid,1-[oxo[tetrahydro-2-hydroxy-6-[14-hydroxy-22-(4-hydroxy-3-methoxycyclohexyl)-2,13-dimethoxy-3,9,11,15,17,21-hexamethyl-12,18-dioxo-3,5,7,15,19-docosapentaenyl]-3-methyl-2H-pyran-2-yl]acetyl]-,[2R-[2a,2(S*),3a,6b[2S*,3E,5E,7E,9S*,11R*,13R*,14R*,15E,17R*,19E,21R*,22(1S*,3R*,4R*)]]]-
Secorapamycin A is a small molecule activator of the protein tyrosine phosphatase-1b (PTP-1B). Secorapamycin A binds to PTP-1B and increases its activity, resulting in inhibition of the nuclear factor kappa B (NF-κB) pathway. Secorapamycin A has been shown to inhibit ion channels, such as potassium channels, and to bind to antibodies. This drug also binds to receptors, including ligand binding domain on the human epidermal growth factor receptor 2 (HER2), which is expressed in some breast cancer cells. Secorapamycin A has also been found to inhibit cell proliferation by inhibiting protein synthesis.
Propriedades químicas
Consulta técnica sobre: 3D-XFA43827 Secorapamycin A
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.